share_log

科濟藥業-B：年度業績公告截至2023年12月31日止年度

CARSGEN-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 26 07:32
Summary by Moomoo AI
科濟藥業-B於2023年12月31日公佈年度業績，報告期內淨虧損為人民幣748百萬元，較上年度的人民幣892百萬元減少人民幣144百萬元。經調整淨虧損為人民幣733百萬元，較上年度的人民幣848百萬元減少人民幣115百萬元。現金及銀行結餘為人民幣1,850百萬元，較上年度的人民幣2,268百萬元減少人民幣418百萬元。公司在美國及中國的技術創新、產品管線及業務運營方面取得進展，並於2024年3月1日收到國家藥監局的通知，附條件批准賽愷澤®新藥上市申請。此外，公司已經對CGMP進行了全面的回顧及改進，並正與FDA緊密配合，解決檢查發現的問題。公司與華東醫藥及美德納公司就商業化合作協議取得進展，並於2023年1月收取人民幣200百萬元（含增值稅）的款項。
科濟藥業-B於2023年12月31日公佈年度業績，報告期內淨虧損為人民幣748百萬元，較上年度的人民幣892百萬元減少人民幣144百萬元。經調整淨虧損為人民幣733百萬元，較上年度的人民幣848百萬元減少人民幣115百萬元。現金及銀行結餘為人民幣1,850百萬元，較上年度的人民幣2,268百萬元減少人民幣418百萬元。公司在美國及中國的技術創新、產品管線及業務運營方面取得進展，並於2024年3月1日收到國家藥監局的通知，附條件批准賽愷澤®新藥上市申請。此外，公司已經對CGMP進行了全面的回顧及改進，並正與FDA緊密配合，解決檢查發現的問題。公司與華東醫藥及美德納公司就商業化合作協議取得進展，並於2023年1月收取人民幣200百萬元（含增值稅）的款項。
KOJI PHARMACEUTICAL-B ANNOUNCED ITS ANNUAL RESULTS ON 31 DECEMBER 2023 WITH A NET LOSS OF RMB748 MILLION FOR THE REPORTING PERIOD, A DECREASE OF RMB892 MILLION FROM THE PREVIOUS YEAR'S RMB144 MILLION. Adjusted net loss was RMB733 million, a decrease of RMB115 million from RMB848 million in the previous year. Cash and bank balances were RMB1,850 million, a decrease of RMB2,268 million from RMB2,268 million in the previous year. The Company has made progress in technical innovation, product pipeline and business operations in the United States and China and received a notice from the National Drug Administration on March 1, 2024 with conditions to approve the application for new marketing of Saikaize®. In addition, the company has conducted a comprehensive review and improvement of cGMP and is working closely with the FDA to address the issues found by the inspection. The company made progress on the commercialization cooperation agreement with East China Pharmaceuticals and Medner and collected RMB200 million (VAT included) in January 2023.
KOJI PHARMACEUTICAL-B ANNOUNCED ITS ANNUAL RESULTS ON 31 DECEMBER 2023 WITH A NET LOSS OF RMB748 MILLION FOR THE REPORTING PERIOD, A DECREASE OF RMB892 MILLION FROM THE PREVIOUS YEAR'S RMB144 MILLION. Adjusted net loss was RMB733 million, a decrease of RMB115 million from RMB848 million in the previous year. Cash and bank balances were RMB1,850 million, a decrease of RMB2,268 million from RMB2,268 million in the previous year. The Company has made progress in technical innovation, product pipeline and business operations in the United States and China and received a notice from the National Drug Administration on March 1, 2024 with conditions to approve the application for new marketing of Saikaize®. In addition, the company has conducted a comprehensive review and improvement of cGMP and is working closely with the FDA to address the issues found by the inspection. The company made progress on the commercialization cooperation agreement with East China Pharmaceuticals and Medner and collected RMB200 million (VAT included) in January 2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more